Mechanisms of bone anabolism regulated by statins

Bioscience Reports

Volumn 32, Issue 6, 2012, Pages 511-519

  Ruan, Feng ^a,b   Zheng, Qiang ^a   Wang, Jinfu ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Mesenchymal stem cell (MSC); Osteoclastogenesis; Osteogenesis; Osteoporosis; Statins

Indexed keywords

ARF PROTEIN; ATORVASTATIN; BONE MORPHOGENETIC PROTEIN 2; CERIVASTATIN; COMPACTIN; ESTROGEN RECEPTOR; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PITAVASTATIN; PRAVASTATIN; PROTEIN KINASE B; RAB PROTEIN; RAN PROTEIN; RAS PROTEIN; RHO KINASE; ROSUVASTATIN; SIMVASTATIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; BONE DEVELOPMENT; BONE MASS; BONE MINERALIZATION; CONTROLLED STUDY; DISEASE COURSE; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; MESENCHYMAL STEM CELL; MOLECULAR WEIGHT; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PRENYLATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; BONE AND BONES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; SIGNAL TRANSDUCTION;

EID: 84872375027     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20110118     Document Type: Review

References (86)

1. Editorial Board of Osteoporosis Prevention and Treatment (China White Paper) (2009) White paper on osteoporosis. Chin. J. Health Manag. 3, 148-154
2. Turner, M. R., Camacho, X., Fischer, H. D., Austin, P. C., Anderson, G. M., Rochon, P. A. and Lipscombe, L. L. (2011) Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ 342, d2238
3. Schilcher, J., Michaelsson, K. and Aspenberg, P. (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N. Engl. J. Med. 364, 1728-1737
4. Wysowski, D. K. (2009) Reports of esophageal cancer with oral bisphosphonate Use. N. Engl. J. Med. 360, 89-90
5. Wysowski, D. K. (2010) Oral bisphosphonates and oesophageal cancer. BMJ 341, c4506
6. Mundy, G., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B., Zhao, M. and Gutierrez, G. (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946-1949 (Pubitemid 129515901)
7. Maeda, T., Matsunuma, A., Kawane, T. and Horiuchi, N. (2001) Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 280, 874-877 (Pubitemid 32924513)
8. Ohnaka, K., Shimoda, S., Nawata, H., Shimokawa, H., Kaibuchi, K., Iwamoto, Y. and Takayanagi, R. (2001) Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem. Biophys. Res. Commun. 287, 337-342 (Pubitemid 32917601)
9. Leem, K., Park, S. Y., Lee, D. H. and Kim, H. (2002) Lovastatin increases longitudinal bone growth and bone morphogenetic protein-2 levels in the growth plate of Sprague-Dawley rats. Eur. J. Pediatr. 161, 406-407 (Pubitemid 34744018)
10. Thylin, M. R., McConnell, J. C., Schmid, M. J., Reckling, R. R., Ojha, J., Bhattacharyya, I., Marx, D. B. and Reinhardt, R. A. (2002) Effects of simvastatin gels on murine calvarial bone. J. Periodont. 73, 1141-1148 (Pubitemid 35256265)
11. Sugiyama, M., Kodama, T., Konishi, K., Abe, K., Asami, S. and Oikawa, S. (2000) Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 271, 688-692 (Pubitemid 30444689)
12. Kim, C. H., Choi, K. S., Lee, K., Park, J. U. and Pyo, S. W. (2009) The effect of simvastatin on osteogenic differentiation of human buccal fat pad-derived stem cells. Tissue Eng. Regen. Med. 6, 2-8
13. Baek, K. H., Lee, W. Y., Oh, K. W., Tae, H. J., Lee, J. M., Lee, E. J., Han, J. H., Kang, M. I., Cha, B. Y., Lee, K. W. et al. (2005) The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J. Korean Med. Sci. 20, 438-444
14. Ruiz-Gaspa, S., Nogues, X., Enjuanes, A., Monllau, J. C., Blanch, J., Carreras, R., Mellibovsky, L., Grinberg, D., Balcells, S., Diez-Perez, A. and Pedro-Botet, J. (2007) Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J. Cell. Biochem. 101, 1430-1438 (Pubitemid 47242774)
15. Masuzaki, T., Ayukawa, Y., Moriyama, Y., Jinno, Y., Atsuta, I., Ogino, Y. and Koyano, K. (2010) The effect of a single remote injection of statin-impregnated poly(lactic-co-glycolic acid) microspheres on osteogenesis around titanium implants in rat tibia. Biomaterials 31, 3327-3334
16. Wong, R. and Rabie, A. (2003) Statin collagen grafts used to repair defects in the parietal bone of rabbits. Br. J. Oral Maxillofac. Surg. 41, 244-248 (Pubitemid 37184465)
17. Chuengsamarn, S., Rattanamongkoulgul, S., Suwanwalaikorn, S., Wattanasirichaigoon, S. and Kaufman, L. (2010) Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 46, 1011-1015
18. Li, X. D., Cui, Q. J., Kao, C. H., Wang, G. J. and Balian, G. (2003) Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPAR gamma 2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 33, 652-659
19. Wang, G. J., Cui, Q. and Balian, G. (2000) The pathogenesis and prevention of steroid induced osteonecrosis. Clin. Orthop. Rel. Res. 370, 295-310 (Pubitemid 30059165)
20. Goldstein, J. L. and Brown, M. S. (1990) Regulation of the mevalonate pathway. Nature 343, 425-430
21. Tong, H. X., Holstein, S. A. and Hohl, R. J. (2005) Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal. Biochem. 336, 51-59 (Pubitemid 39593499)
22. Weivoda, M. M. and Hohl, R. J. (2011) Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation. Endocrinology 152, 3113-3122
23. Weivoda, M. M. and Hohl, R. J. (2011) The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation. J. Cell. Biochem. 112, 1506-1513
24. Wiemer, A. J., Tong, H., Swanson, K. M. and Hohl, R. J. (2007) Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem. Biophys. Res. Commun. 353, 921-925 (Pubitemid 46080385)
25. Yoshida, T., Asanuma, M., Grossmann, L., Fuse, M., Shibata, T., Yonekawa, T., Tanaka, T., Ueno, K., Yasuda, T., Saito, Y. and Tatsuno, I. (2006) Geranylgeranyl-pyrophosphate (GGPP) synthase is down-regulated during differentiation of osteoblastic cell line MC3T3M-E1. FEBS Lett. 580, 5203-5207 (Pubitemid 44415791)
26. Ohnaka, K., Shimoda, S., Nawata, H., Shimokawa, H., Kaibuchi, K., Iwamoto, Y. and Takayanagi, R. (2001) Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem. Biophys. Res. Commun. 287, 337-342 (Pubitemid 32917601)
27. Maeda, T., Matsunuma, A., Kurahashi, I., Yanagawa, T., Yoshida, H. and Horiuchi, N. (2004) Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J. Cell. Biochem. 92, 458-471
28. Duque, G., Vidal, C. and Rivas, D. (2011) Protein isoprenylation regulates osteogenic differentiation of mesenchymal stem cells: effect of alendronate, and farnesyl and geranylgeranyl transferase inhibitors. Br. J. Pharmacol. 162, 1109-1118
29. Zhang, F. L. and Casey, P. J. (1996) Protein prenylation: Molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241-269 (Pubitemid 26250610)
30. Casey, P. J. and Seabra, M. C. (1996) Protein prenyltransferases. J. Biol. Chem. 271, 5289-5292 (Pubitemid 26083855)
31. Laufs, U. and Liao, J. K. (1998) Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho GTPase. J. Biol. Chem. 273, 24266-24271 (Pubitemid 28435775)
32. Ghosh-Choudhury, N., Mandal, C. C. and Choudhury, G. G. (2007) Statin-induced Ras activation integrates the phosphatidylinositol 3-kinase signal to Akt and MAPK for bone morphogenetic protein-2 expression in osteoblast differentiation. J. Biol. Chem. 282, 4983-4993 (Pubitemid 47100994)
33. Chen, P. Y., Sun, J. S., Tsuang, Y. H., Chen, M. H., Weng, P. W. and Lin, F. H. (2010) Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr. Res. 30, 191-199
34. Cho, K. J., Hill, M. M., Chigurupati, S., Du, G., Parton, R. G. and Hancock, J. F. (2011) Therapeutic levels of the hydroxmethyl-glutaryl-coenzyme A reductase inhibitor lovastatin activate Ras signaling via phospholipase D2. Mol. Cell. Biol. 31, 1110-1120
35. Tsuji, K., Bandyopadhyay, A., Harfe, B. D., Cox, K., Kakar, S., Gerstenfeld, L., Einhorn, T., Tabin, C. J. and Rosen, V. (2006) BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nature Genet. 38, 1424-1429 (Pubitemid 44837565)
36. Lissenberg-Thunnissen, S. N., de Gorter, D. J. J., Sier, C. F. M. and Schipper, I. B. (2011) Use and efficacy of bone morphogenetic proteins in fracture healing. Int. Orthop. 35, 1271-1280
37. Smith, D. M., Cooper, G. M., Mooney, M. P., Marra, K. G. and Losee, J. E. (2008) Bone morphogenetic protein 2 therapy for craniofacial surgery. J. Craniofac. Surg. 19, 1244-1259
38. Reference deleted
39. Monjo, M., Rubert, M., Ellingsen, J. and E.Lyngstadaas, S. P. (2009) Rosuvastatin promotes osteoblast differentiation and regulates oatp1b1 gene expression in MC3T3-e1 cells. Bone 44, S311
40. Franceschi, R. T., Xiao, G., Jiang, D., Gopalakrishnan, R., Yang, S. and Reith, E. (2003) Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation. Connect. Tissue Res. 44 (Suppl. 1), 109-116 (Pubitemid 36395431)
41. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L. and Karsenty, G. (1997) Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89, 747-54 (Pubitemid 27516177)
42. Reference deleted
43. Franceschi, R. T. and Xiao, G. Z. (2003) Regulation of the osteoblast-specific transcription factor, runx2: responsiveness to multiple signal transduction pathways. J. Cell. Biochem. 88, 446-454 (Pubitemid 36158266)
44. Vukelic, S., Stojadinovic, O., Pastar, I., Vouthounis, C., Krzyzanowska, A., Das, S., Samuels, H. H. and Tomic-Canic, M. (2010) Farnesyl pyrophosphate inhibits epithelialization and wound healing through the glucocorticoid receptor. J. Biol. Chem. 285, 1980-1988
45. Horsch, K., de Wet, H., Schuurmans, M. M., Allie-Reid, F., Cato, A., Cunningham, J., Burrin, J. M., Hough, F. S. and Hulley, P. A. (2007) Mitogen-activated protein kinase phosphatase 1/dual specificity phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol. Endocrinol. 21, 2929-2940 (Pubitemid 350225576)
46. Canalis, E. and Delany, A. M. (2002) Mechanisms of glucocorticoid action in bone. Ann. N.Y. Acad. Sci. 966, 73-81 (Pubitemid 34729163)
47. Jilka, R. L., Weinstein, R. S., Bellido, T., Parfitt, A. M. and Manolagas, S. C. (1998) Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner. Res. 13, 793-802 (Pubitemid 28224195)
48. Weinstein, R. S. and Manolagas, S. C. (2000) Apoptosis and osteoporosis. Am. J. Med. 108, 153-164 (Pubitemid 30064426)
49. Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M. and Manolagas, S. C. (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104, 439-446 (Pubitemid 29534328)
50. Piek, E., Heldin, C. H. and Ten Dijke, P. (1999) Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J. 13, 2105-2124
51. Centrella, M., Mccarthy, T. L. and Canalis, E. (1987) Transforming growth-factor-β is a bifunctional regulator of replication and collagen-synthesis in osteoblast-enriched cell-cultures from fetal-rat bone. J. Biol. Chem. 262, 2869-2874
52. Heldin, C. H., Miyazono, K. and TenDijke, P. (1997) TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471 (Pubitemid 28013118)
53. Borton, A. J., Frederick, J. P., Datto, M. B., Wang, X. F. and Weinstein, R. S. (2001) The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J. Bone Miner. Res. 16, 1754-1764 (Pubitemid 32911480)
54. Sowa, H., Kaji, H., Yamaguchi, T., Sugimoto, T. and Chihara, K. (2002) Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells. J. Bone Miner. Res. 17, 1190-1199 (Pubitemid 34680495)
55. Kaji, H., Naito, J., Inoue, Y., Sowa, H., Sugimoto, T. and Chihara, K. (2008) Statin suppresses apoptosis in osteoblastic cells: role of transforming growth factor-β-Smad3 pathway. Horm. Metab. Res. 40, 746-751
56. Inman, G. J., Nicolas, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J. and Hill, C. S. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65-74 (Pubitemid 34680517)
57. Manolagas, S. C. (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115-137
58. Boyle, W. J., Simonet, W. S. and Lacey, D. L. (2003) Osteoclast differentiation and activation. Nature 423, 337-342 (Pubitemid 40852708)
59. Luckman, S. P., Hughes, D. E., Coxon, F. P., Graham, R., Russell, G. and Rogers, M. J. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13, 581-589 (Pubitemid 28163009)
60. Woo, J. T., Kasai, S., Stern, P. H. and Nagai, K. (2000) Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J. Bone Miner. Res. 15, 650-662 (Pubitemid 30174019)
61. Syed, F. and Khosla, S. (2005) Mechanisms of sex steroid effects on bone. Biochem. Biophys. Res. Commun. 328, 688-696 (Pubitemid 40214350)
62. Kaji, H., Kanatani, M., Sugimoto, T. and Chihara, K. (2005) Statins modulate the levels of osteoprotegerin/receptor activator of NF kappa B ligand mRNA in mouse bone-cell cultures. Horm. Metab. Res. 37, 589-592 (Pubitemid 41597568)
63. Bord, S., Horner, A., Beavan, S. and Compston, E. (2001) Estrogen receptors alpha and beta are differentially expressed in developing human bone. J. Clin. Endocrinol. Metab. 86, 2309-2314 (Pubitemid 32472956)
64. Wang, J. W., Xu, S. W., Yang, D. S. and Lv, R. K. (2007) Locally applied simvastatin promotes fracture healing in ovariectomized rat. Osteoporosis Int. 18, 1641-1650 (Pubitemid 47620312)
65. De Leo, V., Morgante, G., la Marca, A., Lanzetta, D., Cobellis, L. and Petraglia, F. (2003) Combination of statins and hormone replacement therapy in postmenopausal women is associated with increased bone mineral density. Gynecol. Endocrinol. 17, 329-332 (Pubitemid 37083040)
66. Song, C. L., Wang, J. Y., Song, Q. S., Li, X., Chen, Z. Q., Ma, Q. J., Liu, Z. J., Jia, H. T. and Dang, G. T. (2008) Simvastatin induces estrogen receptor-alpha (ER-alpha) in murine bone marrow stromal cells. J. Bone Miner. Metab. 26, 213-217 (Pubitemid 351677840)
67. Li, X., Song, Q. S., Wang, J. Y., Leng, H. J., Chen, Z. Q., Liu, Z. J., Dang, G. T. and Song, C. L. (2010) Simvastatin induces estrogen receptor-alpha expression in bone, restores bone loss, and decreases ERalpha expression and uterine wet weight in ovariectomized rats. J. Bone Miner. Metab. 29, 396-403
68. Khosla, S. (2001) Minireview: The OPG/RANKL/RANK system. Endocrinology 142, 5050-5055
69. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T. et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (Pubitemid 27199902)
70. Davis, A. P., Witte, D. P., Hsiehli, H. M., Potter, S. S. and Capecchi, M. R. (1995) Absence of radius and ulna in mice lacking hoxa-11 and hoxd-11. Nature 375, 791-795
71. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S. et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (Pubitemid 28180851)
72. Reference deleted
73. Ahn, K. S., Sethi, G., Chaturvedi, M. M. and Aggarwal, B. B. (2008) Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappa B ligand through modulation of NF-kappa B pathway. Int. J. Cancer 123, 1733-1740
74. Franzoso, G., Carlson, L., Xing, L. P., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F. and Siebenlist, U. (1997) Requirement for NF-kappa B in osteoclast and B-cell development. Genes Dev. 11, 3482-3496 (Pubitemid 28023969)
75. Ayukawa, Y., Yasukawa, E., Moriyama, Y., Ogino, Y., Wada, H., Atsuta, I. and Koyano, K. (2009) Local application of statin promotes bone repair through the suppression of osteoclasts and the enhancement of osteoblasts at bone-healing sites in rats. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 107, 336-342
76. Han, G. H., Chen, Y. P., Hou, J. H., Liu, C., Chen, C., Zhuang, J. L. and Meng, W. (2010) Effects of simvastatin on relapse and remodeling of periodontal tissues after tooth movement in rats. Am. J. Orthod. Dentofacial Orthop. 138, 550.e1-550.e7
77. Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C. and Riggs, B. L. (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140, 4367-4370 (Pubitemid 30647136)
78. Saika, M., Inoue, D., Kido, S. and Matsumoto, T. (2001) 17 β-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 142, 2205-2212 (Pubitemid 32473073)
79. Shevde, N. K., Bendixen, A. C., Dienger, K. M. and Pike, J. W. (2000) Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. U.S.A. 97, 7829-7834 (Pubitemid 30460733)
80. Chan, K. A., Andrade, S. E., Boles, M., Buist, D. S., Chase, G. A., Donahue, J. G., Goodman, M. J., Gurwitz, J. H., LaCroix, A. Z. and Platt, R. (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355, 2185-2188 (Pubitemid 30394324)
81. Bauer, D. C., Mundy, G. R., Jamal, S. A., Black, D. M., Cauley, J. A., Ensrud, K. E., van der Klift, M. and Pols, H. (2004) Use of statins and fracture - results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch. Intern. Med. 164, 146-152 (Pubitemid 38140400)
82. Rejnmark, L., Olsen, M. L., Johnsen, S. P., Vestergaard, P., Sorensen, H. T. and Mosekilde, L. (2004) Hip fracture risk in statin users - a population-based Danish case-control study. Osteoporosis Int. 15, 452-458 (Pubitemid 38843173)
83. Schoofs, M., Sturkenboom, M., van der Klift, M., Hofman, A., AP Pols, H. and Stricker, B. (2004) HMG-CoA reductase inhibitors and the risk of vertebral fracture. J. Bone Miner. Res. 19, 1525-1530 (Pubitemid 41094355)
84. Reid, I. R., Hague, W., Emberson, J., Baker, J., Tonkin, A., Hunt, D., MacMahon, S. and Sharpe, N. (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term intervention with pravastatin in ischaemic disease. Lancet 357, 509-512 (Pubitemid 32173587)
85. Reid, I. R., Tonkin, A. and Cannon, C. P. (2005) Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial - secondary analysis of a randomized controlled trial. Bone 37, 190-191 (Pubitemid 40962426)
86. Tikiz, C., Tikiz, H., Taneli, F., Gumuser, G. and Tuzun, C. (2005) Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study. Clin. Rheumatol. 24, 447-452 (Pubitemid 43055032)